Search results for "intranasal fentanyl"

showing 4 items of 4 documents

Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.

2014

Abstract The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen. Each patient randomly received INFS or FPNS in doses proportional to opioid dosages used for background analgesia for 2 pairs of episodes. For each episode of breakthrough pain, pain intensity and adverse effects intensity were recorded just before starting the INFS or FPNS (T0) and 5 minutes (T5), 10 minutes (T10), and 20 minutes (T20) after the administration of the nasal drugs. Sixty-nine patients were studied. …

AdultMalefentanyl pectin nasal spraymedicine.medical_treatmentAnalgesicSettore MED/42 - Igiene Generale E ApplicataFentanylrapid-onset opioidsNeoplasmsparasitic diseasesMedicineHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overDose-Response Relationship Drugbusiness.industryBreakthrough Painintranasal fentanylNasal SpraysMiddle AgedCancer pain; breakthrough pain; fentanyl pectin nasal spray; intranasal fentanyl; rapid-onset opioidsAnalgesics OpioidFentanylRegimenAnesthesiology and Pain MedicineCross-Sectional StudiesNeurologyOpioidNasal sprayAnesthesiaPectinsNasal administrationFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain

2015

Purpose: The aim of the present study was to assess the long-term tolerability and efficacy of intranasal fentanyl (INFS) in opioid-tolerant patients with breakthrough cancer pain (BTP).Patients and methods: A 6 months, observational, prospective, cohort study design was employed to follow advanced cancer patients with BTP receiving INFS under routine clinical practice. Eligible adult cancer patients suffering from BTP had been prescribed INFS at effective doses. Data were collected at T0 and at month intervals for six months. The principal outcomes were the evaluation of possible serious adverse effects with prolonged use of INFS, the efficacy of BTP treatment with INFS, the quality of sle…

AdultMalemedicine.medical_specialtySettore MED/42 - Igiene Generale E ApplicataFentanylCohort StudiesPatient satisfactionNeoplasmsInternal medicineparasitic diseasesHumansPain ManagementMedicineProspective StudiesCancer painAdverse effectProspective cohort studyAdministration IntranasalAgedPain Measurementbusiness.industryBreakthrough PainMiddle AgedTolerabilityDiscontinuationAnalgesics OpioidFentanylBreakthrough pain; Cancer pain; Intranasal fentanyl; Tolerability; OncologyOncologyTolerabilityPatient SatisfactionAnesthesiaIntranasal fentanylFemaleSleepbusinessCancer painmedicine.drugCohort studySupportive Care in Cancer
researchProduct

686 EASE OF USE AND PREFERENCE FOR INTRANASAL FENTANYL SPRAY (INFS) VERSUS ORAL TRANSMUCOSAL FENTANYL CITRATE (OTFC) FOR BREAKTHROUGH CANCER PAIN

2009

medicine.medical_specialtyAnesthesiology and Pain MedicineIntranasal Fentanyl Spraybusiness.industryAnesthesiamedicineCancer painbusinessPreferenceFentaNYL CitrateSurgeryEuropean Journal of Pain
researchProduct

685 EFFICACY OF INTRANASAL FENTANYL SPRAY (INFS) VERSUS ORAL TRANSMUCOSAL FENTANYL CITRATE (OTFC) FOR BREAKTHROUGH CANCER PAIN: OPEN‐LABEL CROSSOVER …

2009

medicine.medical_specialtyAnesthesiology and Pain MedicineIntranasal Fentanyl Spraybusiness.industryAnesthesiamedicineOpen labelCancer painbusinessCrossover studyFentaNYL CitrateSurgeryEuropean Journal of Pain
researchProduct